Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients

Gul M. Mustafa, Larry Denner, John R. Petersen, Cornelis Elferink

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Hepatocellular carcinoma (HCC)-related mortality is high because early detection modalities are hampered by inaccuracy, expense and inherent procedural risks. Thus there is an urgent need for minimally invasive, highly specific and sensitive biomarkers that enable early disease detection when therapeutic intervention remains practical. Successful therapeutic intervention is predicated on the ability to detect the cancer early. Similar unmet medical needs abound in most fields of medicine and require novel methodological approaches. Proteomic profiling of body fluids presents a sensitive diagnostic tool for early cancer detection. Here we describe such a strategy of comparative proteomics to identify potential serum-based biomarkers to distinguish high-risk chronic hepatitis C virus infected patients from HCC patients. In order to compensate for the extraordinary dynamic range in serum proteins, enrichment methods that compress the dynamic range without surrendering proteome complexity can help minimize the problems associated with many depletion methods. The enriched serum can be resolved using 2D-difference in-gel electrophoresis and the spots showing statistically significant changes selected for identification by liquid chromatographytandem mass spectrometry. Subsequent quantitative verification and validation of these candidate biomarkers represent an obligatory and rate-limiting process that is greatly enabled by selected reaction monitoring (SRM). SRM is a tandem mass spectrometry method suitable for identification and quantitation of target peptides within complex mixtures independent on peptidespecific antibodies. Ultimately, multiplexed SRM and dynamic multiple reaction monitoring can be utilized for the simultaneous analysis of a biomarker panel derived from support vector machine learning approaches, which allows monitoring a specific disease state such as early HCC. Overall, this approach yields high probability biomarkers for clinical validation in large patient cohorts and represents a strategy extensible to many diseases.

Original languageEnglish (US)
Pages (from-to)1312-1324
Number of pages13
JournalWorld Journal of Hepatology
Volume7
Issue number10
DOIs
StatePublished - 2015

Fingerprint

Hepatitis C
Proteomics
Hepatocellular Carcinoma
Biomarkers
Body Fluids
Chronic Hepatitis C
Proteome
Tandem Mass Spectrometry
Complex Mixtures
Serum
Early Detection of Cancer
Hepacivirus
Electrophoresis
Blood Proteins
Early Diagnosis
Mass Spectrometry
Gels
Medicine
Peptides
Mortality

Keywords

  • Biomarkers
  • Early detection
  • Hepatocellular carcinoma
  • Selected reaction monitoring
  • Targeted proteomics

ASJC Scopus subject areas

  • Hepatology

Cite this

Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients. / Mustafa, Gul M.; Denner, Larry; Petersen, John R.; Elferink, Cornelis.

In: World Journal of Hepatology, Vol. 7, No. 10, 2015, p. 1312-1324.

Research output: Contribution to journalArticle

@article{d2e74fee59164720b1496f12a973cc1e,
title = "Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients",
abstract = "Hepatocellular carcinoma (HCC)-related mortality is high because early detection modalities are hampered by inaccuracy, expense and inherent procedural risks. Thus there is an urgent need for minimally invasive, highly specific and sensitive biomarkers that enable early disease detection when therapeutic intervention remains practical. Successful therapeutic intervention is predicated on the ability to detect the cancer early. Similar unmet medical needs abound in most fields of medicine and require novel methodological approaches. Proteomic profiling of body fluids presents a sensitive diagnostic tool for early cancer detection. Here we describe such a strategy of comparative proteomics to identify potential serum-based biomarkers to distinguish high-risk chronic hepatitis C virus infected patients from HCC patients. In order to compensate for the extraordinary dynamic range in serum proteins, enrichment methods that compress the dynamic range without surrendering proteome complexity can help minimize the problems associated with many depletion methods. The enriched serum can be resolved using 2D-difference in-gel electrophoresis and the spots showing statistically significant changes selected for identification by liquid chromatographytandem mass spectrometry. Subsequent quantitative verification and validation of these candidate biomarkers represent an obligatory and rate-limiting process that is greatly enabled by selected reaction monitoring (SRM). SRM is a tandem mass spectrometry method suitable for identification and quantitation of target peptides within complex mixtures independent on peptidespecific antibodies. Ultimately, multiplexed SRM and dynamic multiple reaction monitoring can be utilized for the simultaneous analysis of a biomarker panel derived from support vector machine learning approaches, which allows monitoring a specific disease state such as early HCC. Overall, this approach yields high probability biomarkers for clinical validation in large patient cohorts and represents a strategy extensible to many diseases.",
keywords = "Biomarkers, Early detection, Hepatocellular carcinoma, Selected reaction monitoring, Targeted proteomics",
author = "Mustafa, {Gul M.} and Larry Denner and Petersen, {John R.} and Cornelis Elferink",
year = "2015",
doi = "10.4254/wjh.v7.i10.1312",
language = "English (US)",
volume = "7",
pages = "1312--1324",
journal = "World Journal of Hepatology",
issn = "1948-5182",
publisher = "Baishideng Publishing Group",
number = "10",

}

TY - JOUR

T1 - Targeted proteomics for biomarker discovery and validation of hepatocellular carcinoma in hepatitis C infected patients

AU - Mustafa, Gul M.

AU - Denner, Larry

AU - Petersen, John R.

AU - Elferink, Cornelis

PY - 2015

Y1 - 2015

N2 - Hepatocellular carcinoma (HCC)-related mortality is high because early detection modalities are hampered by inaccuracy, expense and inherent procedural risks. Thus there is an urgent need for minimally invasive, highly specific and sensitive biomarkers that enable early disease detection when therapeutic intervention remains practical. Successful therapeutic intervention is predicated on the ability to detect the cancer early. Similar unmet medical needs abound in most fields of medicine and require novel methodological approaches. Proteomic profiling of body fluids presents a sensitive diagnostic tool for early cancer detection. Here we describe such a strategy of comparative proteomics to identify potential serum-based biomarkers to distinguish high-risk chronic hepatitis C virus infected patients from HCC patients. In order to compensate for the extraordinary dynamic range in serum proteins, enrichment methods that compress the dynamic range without surrendering proteome complexity can help minimize the problems associated with many depletion methods. The enriched serum can be resolved using 2D-difference in-gel electrophoresis and the spots showing statistically significant changes selected for identification by liquid chromatographytandem mass spectrometry. Subsequent quantitative verification and validation of these candidate biomarkers represent an obligatory and rate-limiting process that is greatly enabled by selected reaction monitoring (SRM). SRM is a tandem mass spectrometry method suitable for identification and quantitation of target peptides within complex mixtures independent on peptidespecific antibodies. Ultimately, multiplexed SRM and dynamic multiple reaction monitoring can be utilized for the simultaneous analysis of a biomarker panel derived from support vector machine learning approaches, which allows monitoring a specific disease state such as early HCC. Overall, this approach yields high probability biomarkers for clinical validation in large patient cohorts and represents a strategy extensible to many diseases.

AB - Hepatocellular carcinoma (HCC)-related mortality is high because early detection modalities are hampered by inaccuracy, expense and inherent procedural risks. Thus there is an urgent need for minimally invasive, highly specific and sensitive biomarkers that enable early disease detection when therapeutic intervention remains practical. Successful therapeutic intervention is predicated on the ability to detect the cancer early. Similar unmet medical needs abound in most fields of medicine and require novel methodological approaches. Proteomic profiling of body fluids presents a sensitive diagnostic tool for early cancer detection. Here we describe such a strategy of comparative proteomics to identify potential serum-based biomarkers to distinguish high-risk chronic hepatitis C virus infected patients from HCC patients. In order to compensate for the extraordinary dynamic range in serum proteins, enrichment methods that compress the dynamic range without surrendering proteome complexity can help minimize the problems associated with many depletion methods. The enriched serum can be resolved using 2D-difference in-gel electrophoresis and the spots showing statistically significant changes selected for identification by liquid chromatographytandem mass spectrometry. Subsequent quantitative verification and validation of these candidate biomarkers represent an obligatory and rate-limiting process that is greatly enabled by selected reaction monitoring (SRM). SRM is a tandem mass spectrometry method suitable for identification and quantitation of target peptides within complex mixtures independent on peptidespecific antibodies. Ultimately, multiplexed SRM and dynamic multiple reaction monitoring can be utilized for the simultaneous analysis of a biomarker panel derived from support vector machine learning approaches, which allows monitoring a specific disease state such as early HCC. Overall, this approach yields high probability biomarkers for clinical validation in large patient cohorts and represents a strategy extensible to many diseases.

KW - Biomarkers

KW - Early detection

KW - Hepatocellular carcinoma

KW - Selected reaction monitoring

KW - Targeted proteomics

UR - http://www.scopus.com/inward/record.url?scp=84930412268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84930412268&partnerID=8YFLogxK

U2 - 10.4254/wjh.v7.i10.1312

DO - 10.4254/wjh.v7.i10.1312

M3 - Article

VL - 7

SP - 1312

EP - 1324

JO - World Journal of Hepatology

JF - World Journal of Hepatology

SN - 1948-5182

IS - 10

ER -